CN103732240B - G-csf二聚体在制备治疗神经退行性疾病药物中的应用 - Google Patents
G-csf二聚体在制备治疗神经退行性疾病药物中的应用 Download PDFInfo
- Publication number
- CN103732240B CN103732240B CN201280036654.9A CN201280036654A CN103732240B CN 103732240 B CN103732240 B CN 103732240B CN 201280036654 A CN201280036654 A CN 201280036654A CN 103732240 B CN103732240 B CN 103732240B
- Authority
- CN
- China
- Prior art keywords
- csf
- dimer
- monomer
- cell
- complex
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/642—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a cytokine, e.g. IL2, chemokine, growth factors or interferons being the inactive part of the conjugate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Abstract
Description
Claims (7)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201280036654.9A CN103732240B (zh) | 2011-07-25 | 2012-07-24 | G-csf二聚体在制备治疗神经退行性疾病药物中的应用 |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201110209712 | 2011-07-25 | ||
CN201110209712.0 | 2011-07-25 | ||
PCT/CN2012/079106 WO2013013613A1 (zh) | 2011-07-25 | 2012-07-24 | G-csf二聚体在制备治疗神经退行性疾病药物中的应用 |
CN201280036654.9A CN103732240B (zh) | 2011-07-25 | 2012-07-24 | G-csf二聚体在制备治疗神经退行性疾病药物中的应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN103732240A CN103732240A (zh) | 2014-04-16 |
CN103732240B true CN103732240B (zh) | 2015-12-09 |
Family
ID=47600520
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201280036654.9A Active CN103732240B (zh) | 2011-07-25 | 2012-07-24 | G-csf二聚体在制备治疗神经退行性疾病药物中的应用 |
Country Status (7)
Country | Link |
---|---|
US (1) | US9642917B2 (zh) |
EP (1) | EP2737905B1 (zh) |
JP (1) | JP5947891B2 (zh) |
CN (1) | CN103732240B (zh) |
AU (1) | AU2012289433B2 (zh) |
CA (1) | CA2842969C (zh) |
WO (1) | WO2013013613A1 (zh) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102260343A (zh) | 2010-05-25 | 2011-11-30 | 健能隆医药技术(上海)有限公司 | 重组人g-csf二聚体在治疗神经损伤疾病中的用途 |
EP3050570A1 (en) * | 2015-01-31 | 2016-08-03 | Neurovision Pharma GmbH | Pharmaceutical composition consisting of a combination of G-CSF with GM-CSF |
US9876264B2 (en) | 2015-10-02 | 2018-01-23 | At&T Intellectual Property I, Lp | Communication system, guided wave switch and methods for use therewith |
AU2019347876A1 (en) * | 2018-09-28 | 2021-05-13 | Memorial Sloan-Kettering Cancer Center | Stem cell-derived human microglial cells, methods of making and methods of use |
WO2024037633A2 (en) | 2022-08-19 | 2024-02-22 | Evive Biotechnology (Shanghai) Ltd | Formulations comprising g-csf and uses thereof |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002036626A1 (en) * | 2000-11-02 | 2002-05-10 | Maxygen Aps | Single-chain multimeric polypeptides |
Family Cites Families (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP3954004B2 (ja) | 1991-12-26 | 2007-08-08 | 中外製薬株式会社 | 脳機能障害による疾患の予防・治療薬 |
FR2686900B1 (fr) | 1992-01-31 | 1995-07-21 | Rhone Poulenc Rorer Sa | Nouveaux polypeptides ayant une activite de stimulation des colonies de granulocytes, leur preparation et compositions pharmaceutiques les contenant. |
AU4658596A (en) | 1995-02-03 | 1996-08-21 | G.D. Searle & Co. | Novel c-mpl ligands |
US6551799B2 (en) | 1999-12-07 | 2003-04-22 | Genentech, Inc. | Interleukin-22 polypeptides, nucleic acids encoding the same and methods for the treatment of pancreatic disorders |
US6660843B1 (en) | 1998-10-23 | 2003-12-09 | Amgen Inc. | Modified peptides as therapeutic agents |
EP1131333B1 (en) | 1998-10-26 | 2010-06-02 | Wyeth a Corporation of the State of Delaware | ISOLATED NUCLEIC ACID MOLECULES WHICH ENCODE T CELL INDUCIBLE FACTORS (TIFs), THE PROTEINS ENCODED, AND USES THEREOF |
US6274710B1 (en) | 1998-10-26 | 2001-08-14 | Ludwig Institute For Cancer Research | Antibodies which specifically bind T Cell inducible factors (TIFs) |
US7307161B1 (en) | 1999-04-28 | 2007-12-11 | Genetics Institute, Llc | Human Gil-19/AE289 polynucleotides |
AU782496B2 (en) | 1999-07-13 | 2005-08-04 | Bolder Biotechnology, Inc. | Immunoglobulin fusion proteins |
GB0024442D0 (en) | 2000-10-05 | 2000-11-22 | Isis Innovation | Genetic factors affecting the outcome of viral infections |
US20020142964A1 (en) | 2000-11-02 | 2002-10-03 | Nissen Torben Lauesgaard | Single-chain polypeptides |
US6900292B2 (en) | 2001-08-17 | 2005-05-31 | Lee-Hwei K. Sun | Fc fusion proteins of human erythropoietin with increased biological activities |
US6797493B2 (en) | 2001-10-01 | 2004-09-28 | Lee-Hwei K. Sun | Fc fusion proteins of human granulocyte colony-stimulating factor with increased biological activities |
US20080108560A1 (en) | 2002-03-05 | 2008-05-08 | Eli Lilly And Company | Heterologous G-Csf Fusion Proteins |
US7785601B2 (en) | 2002-12-31 | 2010-08-31 | Sygnis Bioscience Gmbh & Co. Kg | Methods of treating neurological conditions with hematopoietic growth factors |
CA2586365A1 (en) | 2004-11-05 | 2006-05-26 | Northwestern University | Use of scf and g-csf in the treatment of cerebral ischemia and neurological disorders |
CN100515491C (zh) | 2005-01-04 | 2009-07-22 | 健能隆医药技术(上海)有限公司 | 白介素-22的医药用途 |
US7625564B2 (en) | 2006-01-27 | 2009-12-01 | Novagen Holding Corporation | Recombinant human EPO-Fc fusion proteins with prolonged half-life and enhanced erythropoietic activity in vivo |
WO2008137571A1 (en) | 2007-05-01 | 2008-11-13 | Florida Atlantic University | Methods of treating neurodegenerative diseases |
WO2008147534A1 (en) | 2007-05-22 | 2008-12-04 | Maxygen Holdings Ltd. | Method for the treatment of neutropenia by administration of a multi-pegylated granulocyte colony stimulating factor (g-csf) variant |
JP5577243B2 (ja) | 2007-05-30 | 2014-08-20 | ポステク アカデミー−インダストリー ファウンデイション | 免疫グロブリン融合タンパク質 |
WO2009019441A2 (en) | 2007-08-03 | 2009-02-12 | Asterion Limited | Granulocyte colony stimulating factor |
CN101361968B (zh) | 2007-08-06 | 2011-08-03 | 健能隆医药技术(上海)有限公司 | 白介素-22在治疗脂肪肝中的应用 |
PT2514436T (pt) | 2007-11-07 | 2018-03-21 | Genentech Inc | Il-22 para utilização no tratamento de distúrbios microbianos |
UA118536C2 (uk) | 2008-07-23 | 2019-02-11 | Амбркс, Інк. | Модифікований поліпептид бичачого гранулоцитарного колонієстимулювального фактора та його застосування |
CA2788096A1 (en) | 2010-01-13 | 2011-07-21 | Amgen Inc. | Il-22-fc and hepcidin activity |
LT2010013A (lt) | 2010-02-10 | 2011-08-25 | Uab Profarma, , | Biologiškai aktyvių granulocitų kolonijas stimuliuojančio faktoriaus darinių išskyrimo ir gryninimo būdas |
LT2010012A (lt) | 2010-02-10 | 2011-08-25 | Uab Profarma, , | Granulocitus stimuliuojančio baltymo linijiniai oligomerai su prailginta in vivo gyvavimo trukme |
CN102260343A (zh) | 2010-05-25 | 2011-11-30 | 健能隆医药技术(上海)有限公司 | 重组人g-csf二聚体在治疗神经损伤疾病中的用途 |
CN102380090A (zh) | 2010-08-31 | 2012-03-21 | 健能隆医药技术(上海)有限公司 | G-csf二聚体在治疗嗜中性粒细胞减少症中的应用 |
-
2012
- 2012-07-24 EP EP12817542.9A patent/EP2737905B1/en active Active
- 2012-07-24 US US14/233,739 patent/US9642917B2/en active Active
- 2012-07-24 WO PCT/CN2012/079106 patent/WO2013013613A1/zh active Application Filing
- 2012-07-24 AU AU2012289433A patent/AU2012289433B2/en active Active
- 2012-07-24 JP JP2014521926A patent/JP5947891B2/ja active Active
- 2012-07-24 CA CA2842969A patent/CA2842969C/en active Active
- 2012-07-24 CN CN201280036654.9A patent/CN103732240B/zh active Active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002036626A1 (en) * | 2000-11-02 | 2002-05-10 | Maxygen Aps | Single-chain multimeric polypeptides |
Non-Patent Citations (1)
Title |
---|
Granulocyte-colony stimulating factor (G-CSF) enhances recovery in mouse model of parkinson"s disease;Shijie Song et al.;《Neuroscience letter》;20110131;第487卷(第2期);摘要、第153页 * |
Also Published As
Publication number | Publication date |
---|---|
EP2737905A4 (en) | 2015-03-18 |
AU2012289433B2 (en) | 2017-07-27 |
EP2737905B1 (en) | 2019-09-11 |
WO2013013613A1 (zh) | 2013-01-31 |
US20140248234A1 (en) | 2014-09-04 |
CA2842969A1 (en) | 2013-01-31 |
CA2842969C (en) | 2018-03-27 |
CN103732240A (zh) | 2014-04-16 |
AU2012289433A1 (en) | 2014-03-13 |
JP5947891B2 (ja) | 2016-07-06 |
US9642917B2 (en) | 2017-05-09 |
JP2014521612A (ja) | 2014-08-28 |
EP2737905A1 (en) | 2014-06-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN104066440B (zh) | 白介素-22在治疗和预防神经损伤疾病或神经退行性疾病中的用途 | |
CN103732240B (zh) | G-csf二聚体在制备治疗神经退行性疾病药物中的应用 | |
CN104710535B (zh) | 重组人g-csf二聚体及其在治疗神经系统疾病中的用途 | |
US9963484B2 (en) | Polynucleotide encoding a fusion protein for improving skin conditions | |
JPWO2014098249A1 (ja) | 組織修復活性組成物及びその利用 | |
CN103539861A (zh) | 长效重组人促卵泡激素融合蛋白 | |
US20130211051A1 (en) | Fusion protein containing vegi, and pharmaceutical composition and use thereof | |
KR102414649B1 (ko) | 에리스로포이에틴-유래된 펩타이드, 이의 제조 방법 및 이의 용도 | |
CN106552259A (zh) | 一种融合蛋白及其治疗疾病的用途 | |
CN103239714B (zh) | 用于治疗缺血性疾病的蛋白质及药物组合物 | |
CN114349839A (zh) | 一种热休克蛋白在制备抗胶质瘤药物中的应用及制备方法 | |
JP2001524944A (ja) | 神経障害性疼痛の緩和方法 | |
US20130129708A1 (en) | Self-renewal promoter for neural stem cells and method for using same |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right |
Effective date of registration: 20200611 Address after: 101111 1st, 2nd and 3rd floors, 3rd floor, 99 Kechuang 14th Street, Daxing District, Beijing Economic and Technological Development Zone Patentee after: Beijing Jiannenglong Biopharmaceutical Co.,Ltd. Address before: 201203 Shanghai City, Pudong New Area Road No. 1011, room 307, Zhangjiang hi tech Haley Patentee before: GENERON (SHANGHAI) Corp.,Ltd. |
|
TR01 | Transfer of patent right | ||
CP01 | Change in the name or title of a patent holder |
Address after: 101111 1st, 2nd and 3rd floors, 3rd floor, 99 Kechuang 14th Street, Daxing District, Beijing Economic and Technological Development Zone Patentee after: Yiyi biopharmaceutical (Beijing) Co.,Ltd. Address before: 101111 1st, 2nd and 3rd floors, 3rd floor, 99 Kechuang 14th Street, Daxing District, Beijing Economic and Technological Development Zone Patentee before: Beijing Jiannenglong Biopharmaceutical Co.,Ltd. |
|
CP01 | Change in the name or title of a patent holder | ||
EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20140416 Assignee: NANJING SHUNXIN PHARMACEUTICALS CO., LTD. OF CHIATAI TIANQING PHARMACEUTICAL Group Assignor: Yiyi biopharmaceutical (Beijing) Co.,Ltd. Contract record no.: X2022990000878 Denomination of invention: Application of G-CSF Dimer in Preparation of Drugs for Neurodegenerative Diseases Granted publication date: 20151209 License type: Exclusive License Record date: 20221102 |
|
EE01 | Entry into force of recordation of patent licensing contract |